Comparative Pharmacology
Head-to-head clinical analysis: HUMULIN N versus HUMULIN R PEN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HUMULIN N versus HUMULIN R PEN.
HUMULIN N vs HUMULIN R PEN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Insulin isophane (NPH) is an intermediate-acting insulin that lowers blood glucose by promoting peripheral glucose uptake, especially in muscle and adipose tissue, and inhibiting hepatic glucose production. It binds to the insulin receptor, activating tyrosine kinase activity and downstream signaling pathways.
Insulin is a hormone produced by the pancreas that regulates glucose metabolism. Exogenous insulin replaces endogenous insulin, binding to insulin receptors on cell surfaces, activating tyrosine kinase activity, and promoting glucose uptake, glycogen synthesis, and lipogenesis while inhibiting gluconeogenesis and lipolysis.
0.5-1 unit/kg/day subcutaneously, divided into 2 doses (morning and evening).
Subcutaneous injection, usual starting dose 0.2 to 0.4 units/kg/day divided into two or more injections; total daily insulin requirements may range from 0.5 to 1.0 units/kg/day.
None Documented
None Documented
Terminal half-life: 1.5-2.5 hours (subcutaneous); longer in renal impairment.
Intravenous: plasma half-life is ~5-10 minutes (distribution) and elimination half-life ~1.5-2 hours (reflecting clearance from peripheral compartments). Subcutaneous: prolonged due to absorption rate-limited kinetics; terminal half-life ~5-10 hours.
Renal: 60-80% as intact insulin; hepatic and renal clearance; negligible biliary/fecal elimination.
Primarily renal (hepatic metabolism to inactive metabolites accounts for <20%); ~30-80% of dose excreted unchanged in urine via glomerular filtration.
Category C
Category C
Human Insulin
Human Insulin